Patents by Inventor Nathan Higginson-Scott

Nathan Higginson-Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FC FUSION MOLECULES AND USES THEREOF
    Publication number: 20240167011
    Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.
    Type: Application
    Filed: November 17, 2023
    Publication date: May 23, 2024
    Inventors: Nathan Higginson-Scott, Nathan Rollins, Jordan Anderson, Yanfeng Zhou, Alex Pellerin, Ivan Mascanfroni
  • Tissue targeted immunotolerance with a CD39 effector
    Patent number: 11981715
    Abstract: Methods and compounds for conferring site-specific or local immune privilege, such as to the skin.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: May 14, 2024
    Assignee: Pandion Operations, Inc.
    Inventors: Daniel Rios, Purvi Mande, Joanne L. Viney, Nathan Higginson-Scott, Kevin Lewis Otipoby, Susmita Borthakur, Salvatore Alioto, Lindsay J. Edwards
  • Recombinant ROBO2 proteins, compositions, methods and uses thereof
    Patent number: 11970524
    Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: April 30, 2024
    Assignees: PFIZER INC., BOSTON MEDICAL CENTER CORPORATION
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
  • VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
    Publication number: 20240132592
    Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Inventors: Yen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
  • PANCREAS TARGETED THERAPEUTICS AND USES THEREOF
    Publication number: 20240132591
    Abstract: The disclosure relates to methods and compositions for treating Type 1 diabetes, such as compositions comprising an effector domain linked to a protein that binds to MAdCAM.
    Type: Application
    Filed: February 22, 2022
    Publication date: April 25, 2024
    Applicant: PANDION OPERATIONS, INC.
    Inventors: Daniel RIOS, Kevin OTIPOBY, Joanne L. VINEY, Nathan HIGGINSON-SCOTT
  • IL-2 muteins and uses thereof
    Patent number: 11965008
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: April 23, 2024
    Assignee: PANDION OPERATIONS, INC.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • IL-2 muteins and uses thereof
    Patent number: 11945852
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: April 2, 2024
    Assignee: PANDION OPERATIONS, INC.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • MULTI-PARATOPIC ANTI-PD-1 ANTIBODIES AND USES THEREOF
    Publication number: 20240052034
    Abstract: Multi-paratopic polypeptides that can be used, for example, to modulate the activity of PD-1.
    Type: Application
    Filed: August 19, 2021
    Publication date: February 15, 2024
    Applicant: PANDION OPERATIONS, INC.
    Inventors: Nathan HIGGINSON-SCOTT, Kevin Lewis OTIPOBY, Joanne L. VINEY, Salvatore ALIOTO, Lindsay J. EDWARDS
  • DUAL TARGETED IMMUNE REGULATING COMPOSITIONS
    Publication number: 20240025995
    Abstract: Embodiments provided herein, provide for polypeptides, pharmaceutical compositions, and methods that can be used to target at least two types of cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: June 14, 2023
    Publication date: January 25, 2024
    Inventors: Joanne L. Viney, Nathan Higginson-Scott
  • MADCAM TARGETED THERAPEUTICS AND USES THEREOF
    Publication number: 20240010722
    Abstract: Methods and compounds for conferring site-specific or local immune privilege, such as targeting to a cell expressing MAdCAM.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 11, 2024
    Applicant: PANDION OPERATIONS, INC.
    Inventors: Nathan HIGGINSON-SCOTT, Joanne L. VINEY, Salvatore ALIOTO, Lindsay J. EDWARDS, Kevin Lewis OTIPOBY, Jyothsna VISWESWARAIAH
  • IL-2 muteins and uses thereof
    Patent number: 11779632
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: October 10, 2023
    Assignee: PANDION OPERATION, INC.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • DUAL TARGETED IMMUNE REGULATING COMPOSITIONS
    Publication number: 20230272072
    Abstract: Embodiments provided herein, provide for polypeptides, pharmaceutical compositions, and methods that can be used to target at least two types of cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: October 21, 2022
    Publication date: August 31, 2023
    Inventors: Joanne L. Viney, Nathan Higginson-Scott
  • MAdCAM targeted immunotolerance
    Patent number: 11739146
    Abstract: Methods and compounds for conferring site-specific or local immune privilege, such as targeting to a cell expressing MAdCAM.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: August 29, 2023
    Assignee: PANDION OPERATIONS, INC.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Kevin Lewis Otipoby, Jyothsna Visweswaraiah, Salvatore Alioto, Lindsay J. Edwards, Erik Sampson, Jacob Glanville, David Maurer, Sarah Ives, Christina Pettus, Lauren Schwimmer
  • TISSUE TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
    Publication number: 20230235004
    Abstract: Methods and compounds for conferring site-specific or local immune privilege.
    Type: Application
    Filed: February 19, 2021
    Publication date: July 27, 2023
    Applicant: PANDION OPERATIONS, INC.
    Inventors: Joanne L. VINEY, Nathan HIGGINSON-SCOTT, Kevin OTIPOBY, Daniel RIOS, Susmita BORTHAKUR, Salvatore ALIOTO, Lindsay EDWARDS
  • Targeted immunotolerance
    Patent number: 11466068
    Abstract: Methods and compounds for conferring site-specific or local immune privilege.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: October 11, 2022
    Assignee: Pandion Operations, Inc.
    Inventors: Joanne L. Viney, Nathan Higginson-Scott
  • IL-2 MUTEINS AND USES THEREOF
    Publication number: 20220195003
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: July 27, 2021
    Publication date: June 23, 2022
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • Anti-ROBO2 antibodies, compositions, methods and uses thereof
    Patent number: 11365253
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 21, 2022
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Eric M. Bennett, Nathan Higginson-Scott, Huilan Gao, Zong Sean Juo, Stefano V. Gulla, Christine Huard, Sreekumar R. Kodangattil, Jian Li, Weining Lu, Xueping Fan, David J. Salant
  • IL-2 MUTEINS AND USES THEREOF
    Publication number: 20220185859
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: July 26, 2021
    Publication date: June 16, 2022
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • TARGETED IMMUNOTOLERANCE
    Publication number: 20220041713
    Abstract: Methods and compounds for conferring site-specific or local immune privilege.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 10, 2022
    Inventors: Joanne L. Viney, Nathan Higginson-Scott, Micah Benson, Alan Crane, Kevin Lewis Otipoby
  • IL-2 MUTEINS AND USES THEREOF
    Publication number: 20220031808
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: March 15, 2021
    Publication date: February 3, 2022
    Inventors: Nathan HIGGINSON-SCOTT, Joanne L. VINEY, Jyothsna VISWESWARAIAH, Erik Robert SAMPSON, Kevin Lewis OTIPOBY